SGMOQ SANGAMO THERAP
SANGAMO THERAP (SGMOQ) Insider Activity
What the officers, directors and large holders did with their own shares. Only open-market purchases and sales count toward the totals — grants, option exercises and shares withheld for tax are compensation mechanics, not decisions, and they're listed separately below.
How much of that selling was preplanned? 0% planned / 100% discretionary
Largest single sale: $89.2K.
Where they traded
No open-market insider purchase on record.
Recent open-market activity
| Date | Insider | Role | Action | Shares | Price | Value | Held after |
|---|---|---|---|---|---|---|---|
| Davis Gregory D | Head of Research & Technology | Sell | 69,827 | $0.25 | $17.7K | 115,284 −37.7% of holding | |
| Dubois-Stringfellow Nathalie | SVP-CHIEF DEVELOPMENT OFFICER | Sell | 345,942 | $0.26 | $89.2K | 332,769 −51% of holding |
Form 4s are due within two business days of a transaction, so this is close to real time — unlike the quarterly 13F data on the Institutional tab. A single large sale often reflects a prearranged 10b5-1 plan rather than a fresh view, so read a pattern of sales rather than any one of them.